Cross-linking peptide and repurposed drugs inhibit both entry pathways of SARS-CoV-2
Hanjun Zhao(University of Hong Kong), Kwok‐Yung Yuen(University of Hong Kong - Shenzhen Hospital), Jasper Fuk‐Woo Chan(Hong Kong Baptist University), Hoiyan Lam(Department of Health), Jinxia Zhang(Peking University), Jonathan Daniel Ip(University of Hong Kong), Shibo Jiang(Shanghai Medical College of Fudan University), Jian‐Piao Cai(University of Hong Kong), Wan-Mui Chan(University of Hong Kong), Man Lung Yeung(Hong Kong Science and Technology Parks Corporation), Peng Zheng(National Institute of Standards and Technology), Andrew Chak-Yiu Lee(Hong Kong Science and Technology Parks Corporation), Xinxin Zhou(First Affiliated Hospital Zhejiang University), Chris Chung‐Sing Chan(University of Hong Kong), Allen Wing Ho Chu(University of Hong Kong), Kelvin Kai‐Wang To(Hong Kong Science and Technology Parks Corporation)
Cited by 61
Related Papers
A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster
|The Lancet|2020|9.6k
Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study
|The Lancet Infectious Diseases|2020|3.4k
Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan
|Emerging Microbes & Infections|2020|3.3k
Consistent Detection of 2019 Novel Coronavirus in Saliva
|Clinical Infectious Diseases|2020|2k